Simplifying Global Compliance
FDA Official: Agency May Need Accelerated Withdrawal Process
Washington Drug Letter
The FDA should consider a speedier way to withdraw indications granted under accelerated approval in light of the recent resource-intensive, time-consuming effort to revoke the metastatic breast cancer (MBC) indication for Genentech’s Avastin, CBER Director Karen Midthun says.
To View This Article:
Buy This Article Now
Copyright ©2018. All Rights Reserved.
Design, CMS, Hosting & Web Development :: ePublishing